CW August 2002
Volume 11Issue Number 8 August 2002 ISSN 10593802 Less Endometrial Risk with Aromatase InhibitorThe increased risk of endometrial stimulation and subsequent cancer with tamoxifen is well known. It is thought to be a consequence of the fact that in addition to its primary antiestrogen activity, tamoxifen also has partial estrogenic activity.
Go to Previous Page Go to Next Page Source & Additional Reading 2002 Annual Meeting of the American Society of Clinical Oncology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW August 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
